The biotechnology company reports successful treatment of a third patient in the ongoing clinical trial of its HG-CT-1 CAR-T therapy for relapsed/refractory acute myeloid leukemia.
The biotechnology company has been invited to present at the upcoming DCNY Summit, a prestigious event connecting policymakers, investors, and innovators.
The biotechnology company has announced a manufacturing partnership to advance its lead CAR-T therapy for relapsed/refractory acute myeloid leukemia.
The biotechnology company has raised £235,799 through the exercise of warrants, strengthening its balance sheet without significant dilution to shareholders.
The biotechnology company has raised £450,000 through the exercise of warrants, but at a steep 73.4% discount to the previous closing price, suggesting low market confidence.
The biotechnology company has raised £620,000 through the issue of convertible loan notes to support the ongoing clinical trial of its lead product candidate.
The biotechnology company has announced the outcome of its audit tender process, with PKF Littlejohn LLP set to continue as the external auditor.
The biotechnology company has secured £570,000 in funding to continue Phase 1 trials for its lead cancer treatment candidate.
The biotechnology company reports progress in its clinical trial for a new CAR-T therapy to treat a form of blood cancer.
The biotechnology company has raised £250,000 through a discounted share placement to continue its Phase 1 clinical trials, but the significant discount indicates potential challenges.